How Much Does Target therapy for lung cancer Cost in China?
Target therapy for lung cancer in China typically costs from $1,600 to $13,000. The final price depends on the drug generation, hospital tier, and whether medications are domestic or imported. In the US, similar procedures cost around $120,000 on average. China offers savings of around 94%. Treatment usually includes diagnostic genomic profiling, medication, and specialized oncology consultations.
- Domestic medications: Locally manufactured targeted therapies often cost 50% less than multinational brands.
- Hospital tier: Private international centers in Guangzhou and Chengdu charge 50-100% more than public hospitals.
- Drug generation: Newer third-generation targeted agents command higher premiums than first-generation generic competitors.
- Diagnostic workup: Comprehensive genomic profiling via NGS panels typically adds significant costs to the baseline.
Bookimed Expert Insight: Choosing JCI-accredited centers like Fuda Cancer Hospital provides Western-standard care at significantly lower prices. Fuda Cancer Hospital maintains a partnership with MD Anderson Cancer Center while offering costs 2–3 times lower. For complex cases, Uni-asia Cancer Hospital features experts like Xiao Yueyong, who leads national ablation standards. Patients often benefit from free airport transfers and multilingual interpreters included in these specialized oncology packages.
| China | Turkey | Austria | |
|---|---|---|---|
| Target therapy for lung cancer | from $1,600 | from $5,000 | ≈ $9,000 |
Your Benefits and Guarantees with Bookimed
Transparent Prices & Flexible Installments
No hidden fees – just official clinic prices. Pay at the clinic for Target therapy for lung cancer upon arrival and use a flexible installment plan if needed.
Verified Clinics & Doctors Only
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Target therapy for lung cancer and have the necessary licenses to serve international patients worldwide.
Free 24/7 Assistance
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Target therapy for lung cancer journey.

Your personal Bookimed medical coordinator
- Supports you at every stage
- Helps choose the right clinic and doctor
- Ensures quick and convenient access to information
Discover the Best Target therapy for lung cancer Clinics in China: 3 Verified Options and Prices
Uni-asia Cancer hospital
Liao Zhengyin

Jinshazhou Hospital of Guangzhou University of Chinese Medicine

Target therapy for lung cancer Overview in China
- Lung cancer surgery - from $14,800The procedure removes tumors in the lungs, aids with diagnosis, and generally alleviates symptoms and prolongs life.
- Target therapy for lung cancer - from $1,600This therapy specifically attacks cancer cells, reducing damage to healthy ones. It"s less severe with notable efficacy.
Day 1 - Arrival
- Arrive at the medical facility.
- Complete necessary paperwork and registration procedures.
Day 2 - Pre-Operation
- Consultation with an oncologist and pulmonologist.
- Undergo physical examination and laboratory tests.
- Perform imaging studies like CT or MRI.
Day 3 - Preparing for Target Therapy
- Review of medical history and test results.
- Explanation of the target therapy procedure and its risks.
- Signing of consent forms.
Day 4 - Target Therapy
- Administration of target therapy drugs orally or through IV.
- The process lasts a few hours, no anesthesia required.
- The therapy targets specific genes and proteins of cancer cells.
Day 5 - Post-Operation
- Regular monitoring of vital signs and side effects.
- Stay in the clinic for observation for a day.
Week 1 - Rehabilitation
- Follow-up consultation with oncologist.
- Regular blood tests and imaging studies to monitor progress.
Week 2-4 - Rehabilitation
- Continuation of target therapy at home if advised by the doctor.
- Gradual return to work and daily activities.
Month 2-3 - Final Result
- Complete recovery and return to regular lifestyle.
- Regular check-ups to monitor cancer status.
Please note that the recovery process can vary depending on individual health conditions and how the body responds to the treatment.
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
Our Trusted Doctors
View all Doctors
Liao Zhengyin
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Luo Xiaoping
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).

He Weibing
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.

Xiao Yueyong
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Video Stories from Bookimed Patients
Reviews about Bookimed: Discover Patients' Insights
All reviews


Share this content
Anna Leonova







